Abstract
HAART has substantially decreased mortality and morbidity among HIV-infected patients. We retrospectively analyzed morbidity and mortality in a cohort of HIV-infected adult patients with prolonged and frequent follow up (1987- 2006). The study was divided in pre-HAART and HAART period for comparative reasons. In total, 615 HIV-infected patients (54 females) were included in our study. 144 died during the pre-HAART period (51.4 deaths per 100 patients). During the HAART period only 38 patients died from a total of 335 patients receiving HAART (11.3 deaths per 100 patients); the follow up in this part of the cohort was 2139 persons-years and the death incidence 1.77 deaths/per 100 personyears. The subanalysis excluding patients who died within 3 months from admission showed that death incidence among patients that have been receiving HAART from the time of diagnosis (1.2 deaths per 100 person-years) was slightly lower, compared to the death incidence of patients treated for some time with non-HAART as well (1.58 deaths per 100 personsyears). After the availability of HAART in this unit, the proportion of non-AIDS related deaths increased significantly from 8% to 40% (p < 0.001); infections remained the leading cause of death in both groups of patients. The most common non-AIDS related causes of deaths were cancer and coronary disease. Our data from the studied cohort adds to the relevant literature regarding the dramatic reduction of morbidity and mortality that occurred after the availability of HAART.
Keywords: death incidence, follow-up, causes of death, opportunistic infections, adherence
Current HIV Research
Title: Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study
Volume: 6 Issue: 3
Author(s): George Panos, George Samonis, Vangelis G. Alexiou, Garyfallia A. Kavarnou, Gerasimos Charatsis and Matthew E. Falagas
Affiliation:
Keywords: death incidence, follow-up, causes of death, opportunistic infections, adherence
Abstract: HAART has substantially decreased mortality and morbidity among HIV-infected patients. We retrospectively analyzed morbidity and mortality in a cohort of HIV-infected adult patients with prolonged and frequent follow up (1987- 2006). The study was divided in pre-HAART and HAART period for comparative reasons. In total, 615 HIV-infected patients (54 females) were included in our study. 144 died during the pre-HAART period (51.4 deaths per 100 patients). During the HAART period only 38 patients died from a total of 335 patients receiving HAART (11.3 deaths per 100 patients); the follow up in this part of the cohort was 2139 persons-years and the death incidence 1.77 deaths/per 100 personyears. The subanalysis excluding patients who died within 3 months from admission showed that death incidence among patients that have been receiving HAART from the time of diagnosis (1.2 deaths per 100 person-years) was slightly lower, compared to the death incidence of patients treated for some time with non-HAART as well (1.58 deaths per 100 personsyears). After the availability of HAART in this unit, the proportion of non-AIDS related deaths increased significantly from 8% to 40% (p < 0.001); infections remained the leading cause of death in both groups of patients. The most common non-AIDS related causes of deaths were cancer and coronary disease. Our data from the studied cohort adds to the relevant literature regarding the dramatic reduction of morbidity and mortality that occurred after the availability of HAART.
Export Options
About this article
Cite this article as:
Panos George, Samonis George, Alexiou G. Vangelis, Kavarnou A. Garyfallia, Charatsis Gerasimos and Falagas E. Matthew, Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study, Current HIV Research 2008; 6 (3) . https://dx.doi.org/10.2174/157016208784324976
DOI https://dx.doi.org/10.2174/157016208784324976 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach
Anti-Cancer Agents in Medicinal Chemistry Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art
Current Cancer Therapy Reviews AIDS in African Nonhuman Primate Hosts of SIVs: A New Paradigm of SIV Infection
Current HIV Research Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Ex Vivo Models of HIV Sexual Transmission and Microbicide Development
Current HIV Research Bioactive Cyclohexenones: A Mini Review
Current Bioactive Compounds MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy
Current Medicinal Chemistry Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Effect of the Bioactive Fraction of Argyreia speciosa Leaves Against Gastric Ulcer and Antioxidant Defence System in Rats
Current Traditional Medicine Non-Traditional Drug Targets: High Risk, High Reward
Current Gene Therapy Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Current Pharmaceutical Design Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Costimulation, Coinhibition and Cancer
Current Cancer Drug Targets Vagotomy and Gastric Tumorigenesis
Current Neuropharmacology Carotenoids and Modulation of Cancer: Molecular Targets
Current Pharmacogenomics Unconventional Players on the Striated Muscle Field: microRNAs, Signaling Pathways and Epigenetic Regulators
Current Stem Cell Research & Therapy Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Current Medicinal Chemistry